We retrieved different reports containing different genetic effects of − 1082 A/G, − 819 T/C, and − 592 A/C polymorphisms within the IL-10 (interleukin-10) gene on the susceptibility to clinical atopic dermatitis. Herein, we conducted a meta-analysis to comprehensively assess such a genetic relationship after collecting the available published evidence. STATA 12.0 software was used for the statistical analysis under the allelic, homozygotic, heterozygotic, dominant, recessive and carrier genetic models. By retrieving and screening database literature, a total of 16 eligible case-control studies were finally selected. For the IL-10 -1082 A/G polymorphism, we did not detect a significant difference between atopic dermatitis cases and population-based controls in the overall meta-analysis under the genetic models of allele G vs. A (P = 0.540), GG vs. AA (P = 0.853), AG vs AA (P = 0.265), AG + GG vs AA (P = 0.221), GG vs AA+AG (P = 0.540) and carrier G vs. A (P = 0.643). Moreover, a statistically non-significant association was observed in the most subgroup meta-analyses by the factors of ethnicity, country and Hardy-Weinberg equilibrium. Likewise, the negative results were detected for the synthetic analysis of IL-10 -819 T/C and − 592 C/A polymorphisms. The current evidence does not support a strong genetic relationship between IL-10 -1082 A/G, − 819 T/C and − 592 A/C polymorphisms and the susceptibility to atopic dermatitis.
Introduction: Coat protein complex II (COPII) vesicles mediate cargo transport from the endoplasmic reticulum (ER) to the Golgi apparatus. The composition and assembly of COPII vesicles depend on the transported cargo and are regulated by various accessory factors. However, the mechanisms underlying this variability remain incompletely understood. Methods: Here, we identify Tudor-SN as a novel COPII-associated protein and investigate its role in regulating reproductive development in mice by controlling gonadotropin secretion. We generated global and gonadotrope-specific Tudor-SN knockout mice and examined gonadotropin synthesis, secretion, and COPII assembly using biochemical, imaging, and functional assays. Results: Tudor-SN is physiologically expressed in the adenohypophysis. Global or gonadotrope-specific knockout of Tudor-SN resulted in a phenotype resembling hypogonadotropic hypogonadism, characterized by reduced fertility, underdevelopment of gonadal organs, and decreased sex hormone secretion. Notably, Tudor-SN ablation did not affect gonadotropin synthesis but reduced the secretion of these hormones. Mechanistically, Tudor-SN physically binds to the initiator protein Sar1a and the scaffold protein Sec13 of COPII vesicles to facilitate their assembly. Tudor-SN deficiency disrupted Sar1a–Sec23 complex formation, impairing COPII vesicle biogenesis and gonadotropin trafficking from the ER. Discussion: Our findings reveal that Tudor-SN is a critical regulator of gonadotropin secretion by promoting the initiation of COPII vesicle assembly, thereby linking a cellular role of Tudor-SN to a physiological function in promoting reproductive development in mice.
GAS2L3, a member of the growth arrest-specific 2 protein family, is abnormally upregulated in multiple human cancers, implying its potential oncogenic role. However, the mechanisms underlying its stabilization and accumulation during breast cancer progression remain unclear. This study aimed to clarify the regulatory mechanism and oncogenic role of GAS2L3 in breast cancer. We analyzed the expression and prognostic value of GAS2L3 and its related signaling pathways using public breast cancer databases, and conducted functional assays to assess the malignant phenotypes of breast cancer cells. Mass spectrometry and co-immunoprecipitation were performed to identify and verify TRIM21 as a binding partner of GAS2L3. Ubiquitination and cycloheximide chase assays confirmed that TRIM21 facilitates the ubiquitination and proteasomal degradation of GAS2L3, while immunohistochemical staining of clinical specimens and mouse tissues verified their negative correlation. Rescue experiments further validated this regulatory axis. High GAS2L3 expression predicted poor prognosis and promoted breast cancer cell proliferation, migration, and invasion. Loss of TRIM21-mediated GAS2L3 degradation results in aberrant GAS2L3 accumulation, and the TRIM21–GAS2L3 axis drives breast cancer malignant progression, providing potential prognostic biomarkers and therapeutic targets for breast cancer.